GOG 3012/Niraparib Maintenance Treatment in Patients with HRD Positive Advanced Ovarian Cancer following Response on Front-Line Platinum-Based Chemotherapy


Study Description: This study is being done to help find out if niraparib, the study drug, can help delay worsening of cancer among patients who had a good response to previous treatment with a platinum-type chemotherapy drug.

Contact for Enrollment

    
     (706) 726-5177
    keadams@augusta.edu

    Submit Information Online

Principal Investigator: Sharad Ghamande

Eligibility Criteria: Patients must be able to understand the study procedures and agree to particpate in the study by providing written informed consent. Patients must be female at leaset 18 years of age. Patients must agree to undergo Homologus Recombination Deficiency (HRD) testing. Patients must not be pregnant, breastfeeding, or expecting to conceive children while receiving study treatment and for 3 months after the last dose of study treatment. Please see the protocol for a complete list of the eligibility criteria.

Compensation: No, subjects will not be compensated.

 

Didn't find a study to participate in?

If you don't see specific studies that interest you, please submit your contact information for future studies.